R
Robert M. Grant
Researcher at University of California, San Francisco
Publications - 466
Citations - 29445
Robert M. Grant is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Pre-exposure prophylaxis & Men who have sex with men. The author has an hindex of 76, co-authored 437 publications receiving 26835 citations. Previous affiliations of Robert M. Grant include University of Colorado Denver & Makerere University.
Papers
More filters
Journal ArticleDOI
Use of magnetic resonance imaging to measure intracranial cerebrospinal fluid volume.
Barrie Condon,D. J. Wyper,Robert M. Grant,Jim Patterson,Donald M. Hadley,Graham M. Teasdale,Jack Rowan +6 more
TL;DR: Magnetic resonance imaging was used to measure intracranial extraventricular and ventricular cerebrospinal fluid volume and it may be useful in differential diagnosis and as an objective means of monitoring therapy or progress in conditions such as cerebral atrophy, hydrocephalus, and benign intrac Cranial hypertension.
Journal ArticleDOI
Gods and the one God
TL;DR: The Library of Early Christianity as mentioned in this paper explores the early Christian movement, especially as described in the book of Acts, and uses information about other religions being practiced during the same time period to fill in the story of religious confliect.
Journal ArticleDOI
Human cranial CSF volumes measured by MRI: Sex and age influences
Robert M. Grant,Barrie Condon,A. Lawrence,Donald M. Hadley,Jim Patterson,Ian Bone,Graham M. Teasdale +6 more
TL;DR: The total cranial CSF volume and skull size of males were significantly greater than those of females, but that there was not a statistically significant difference between the ventricular volumes of the sexes.
Journal ArticleDOI
Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls
TL;DR: The combination of tenofovir plus lamivudine or emtricitabine monotherapy provides potent HBV therapy and a solid backbone for HIV combination antiretroviral therapy, and it likely decreases the emergence of HBV resistance.
Journal ArticleDOI
HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial
Teri Liegler,Mohamed Abdel-Mohsen,L. Gordon Bentley,Robert Atchison,Timothy T. Schmidt,Jacqueline Javier,Megha Mehrotra,Christopher Eden,David V. Glidden,Vanessa McMahan,Peter L. Anderson,Peilin Li,Joseph K. Wong,Susan Buchbinder,Juan V. Guanira,Robert M. Grant,Robert M. Grant +16 more
TL;DR: Drug resistance was rare in iPrEx on-study FTC/TDF-randomized seroconverters, and only as low-frequency minor variants, and among those initiating PrEP with acute infection waned rapidly after drug discontinuation.